CDC Plans To Abandon Its PCR Test For COVID In December

The PCR test has been universally used by CDC-controlled hospitals and testing clinics for the past year to trick millions of silly people into thinking they were in danger from COVID, duping them into wearing masks and taking the bio-weapon COVID shot (which has killed thousands of them and injured millions of them). This ruse which allowed the government to shut down the nation — that very PCR test – is now scheduled to be dropped in December 2021.

The government and news networks have obviously known all this time that the PCR test (unapproved by FDA) is a fraud and useful only to trick the public into believing an actual pandemic exists. The test has been nothing but a trick all along. So now the CDC is dropping it unceremoniously this coming December and preparing to replace it with a different test in order to continue defrauding the public.

After experiencing government’s and big pharma’s shenanigans for the past year, anyone who still trusts them must have major mental issues.

The following alert by the CDC was published in July.

07/21/2021: Lab Alert: Changes to CDC RT-PCR for SARS-CoV-2 Testing

CDC's Laboratory Outreach Communication System (LOCS)

Audience: Individuals Performing COVID-19 Testing

Level: Laboratory Alert

After December 31, 2021, CDC will withdraw the request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel, the assay first introduced in February 2020 for detection of SARS-CoV-2 only. CDC is providing this advance notice for clinical laboratories to have adequate time to select and implement one of the many FDA-authorized alternatives.

Visit the FDA website for a list of authorized COVID-19 diagnostic methods. For a summary of the performance of FDA-authorized molecular methods with an FDA reference panel, visit this page.

In preparation for this change, CDC recommends clinical laboratories and testing sites that have been using the CDC 2019-nCoV RT-PCR assay select and begin their transition to another FDA-authorized COVID-19 test. CDC encourages laboratories to consider adoption of a multiplexed method that can facilitate detection and differentiation of SARS-CoV-2 and influenza viruses. Such assays can facilitate continued testing for both influenza and SARS-CoV-2 and can save both time and resources as we head into influenza season. Laboratories and testing sites should validate and verify their selected assay within their facility before beginning clinical testing.

For all whose eyes and ears are functional.


This entry was posted in Articles. Bookmark the permalink.